The multibillion-dollar hunt for what many drugmakers hope will be the next big immunotherapy target has had no shortage of twists and tea-leaf-reading. In the wee hours of Wednesday morning, it got another.
Roche confirmed it accidentally released interim data from a closely watched clinical trial testing whether blocking that target — a protein on T cells known as TIGIT — can enable non-small lung cancer patients to live longer than standard immunotherapy alone.
advertisement
The announcement release came hours after Evercore analyst Umer Raffat emailed investors that he had found a presentation on a Roche media portal, presumably uploaded by accident.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Previous article：
NEJM study measures Covid brain fog, impact on IQ
Next article： Drug repurposing or repositioning? The language matters
Next article： Drug repurposing or repositioning? The language matters
